Opioid vaccine trial aims to block drug high and curb relapse
NCT ID NCT04458545
First seen Apr 30, 2026 · Last updated Apr 30, 2026
Summary
This study tests a vaccine designed to help people with opioid use disorder by training the body to produce antibodies that bind to oxycodone in the blood, reducing its ability to reach the brain and cause a high. The trial involves 45 adults aged 18 to 59 and will check for safety, immune response, and whether the vaccine reduces drug liking. This approach is not a cure but aims to support long-term recovery alongside other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Clinilabs Drug Development Corporation
RECRUITINGEatontown, New Jersey, 07724, United States
Contact Phone: •••-•••-••••
-
New York State Psychiatric Institute: Division on Substance Use Disorders
ACTIVE_NOT_RECRUITINGNew York, New York, 10032, United States
Conditions
Explore the condition pages connected to this study.